AmericanHHM

Innoblative Introduces a Groundbreaking Device for Breast Cancer Patients

SIRA™ RFA Electrosurgical Device (SIRA) from Innoblative is a ground-breaking device for breast cancer patients.

This device has received breakthrough status from the US Food and Drug Administration (FDA).

SIRA is intended for use in breast-conserving surgery (lumpectomy).

Unlike SIRA, conventional RF devices may result in uneven treatment depths and incomplete ablations.

The SIRA device from Innoblative features a unique spherical form that allows for constant and reproducible ablation depths throughout the whole cavity.

The SIRA device is currently being researched for use in breast-conserving surgery and is not yet available for purchase in the United States.

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO Summit - USAHealthcare CMO Summit - USA